SmallCapReview.com has been a leading site for information on small cap stocks, penny stocks and microcaps since 1999.
Spectrum Pharmaceuticals (Nasdaq: SPPI) $5.41. Today announced that updated data from the ZEVALIN (ibritumomab tiuxetan) injection for intravenous use Phase 3 First-line Indolent Trial (FIT) released in an oral presentation at the 52nd American Society of Hematology (ASH) Annual Meeting by independent researchers demonstrated that after a median follow-up of 66.2 months, patients with previously untreated follicular non-Hodgkin’s lymphoma treated with a standard, single-dose infusion of ZEVALIN as part of the ZEVALIN Therapeutic Regimen after partial or complete response to first-line chemotherapy had a nearly three-year advantage in median progression-free survival (PFS) compared to patients treated with either chemotherapy alone or chemotherapy plus rituximab (49 months versus 14 months).
“ZEVALIN is in my opinion the most effective single drug available with an acceptable hematological toxicity profile for the treatment of patients with low-grade malignant follicular non-Hodgkin's lymphoma,” said Anton Hagenbeek, M.D., Ph.D., Professor of Hematology, Academic Medical Center, Amsterdam and principal investigator of the FIT trial who presented the updated data in an oral presentation at ASH. “Hematologists should seriously consider this cost-effective treatment modality, which is relatively easy to administer, for their patients in first remission.”
What They Do: Spectrum Pharmaceuticals is a biotechnology company with fully integrated commercial and drug development operations with a primary focus in oncology.
SPPI is a focus stock at SmallCapReview to learn more visit http://www.smallcapreview.com
EntreMed, Inc. (Nasdaq: ENMD) $6.45. Today announced the presentation of data for its Phase 2 oncology drug candidate, ENMD-2076 an Aurora A/angiogenic kinase inhibitor. Data from the Phase 1 studies with ENMD-2076 in patients with multiple myeloma and relapsed or refractory leukemia were presented by EntreMed investigators during poster sessions at the 2010 American Society of Hematology (ASH) Annual Meeting being held December 4-7 in Orlando, Florida. The ongoing multi-center Phase 2 study with ENMD-2076 in ovarian cancer patients is progressing as planned.
"These data will be instrumental in evaluating additional indications for Phase 2 trials beyond our ongoing Phase 2 study in ovarian cancer patients," commented Dr. Carolyn F. Sidor, EntreMed's Vice President and Chief Medical Officer. "The Phase 1 data in both our hematological and solid tumor studies demonstrate ENMD-2076's potential therapeutic value in a variety of tumor types. In the Phase 1 studies, ENMD-2076 has shown responses in patients with AML, multiple myeloma, and ovarian cancer. Other patients have had tumor reductions or prolonged stable disease with a variety of cancers including hepatocellular, renal cell, neuroendocrine, breast, melanoma and colorectal cancer supporting the activity of ENMD-2076 in treating many types of cancer."
What They Do: EntreMed, Inc. is a clinical-stage pharmaceutical company committed to developing ENMD-2076, a selective angiogenic kinase inhibitor, for the treatment of cancer.
China BAK Battery (Nasdaq: CBAK) $1.70. Today announced that the Company's wholly-owned subsidiary, BAK International Limited, received a subsidy of approximately $7.5 million for its automated high power lithium battery project from the National Development and Reform Commission and Ministry of Industry and Information Technology.
The Company's automated high power lithium battery project was previously selected as a key project of the PRC's National High Technology Research and Development Program, or "863 Program". BAK Tianjin focuses on the research and development, manufacturing and distribution of advanced high-power lithium battery cells for use in light electric vehicles and hybrid electric vehicles.
What They Do: China BAK Battery is a leading global manufacturer of lithium-based battery cells
About SmallCapReview
Copyright SmallCapReview. SmallCapReview.com is a leading site for news on small-caps, penny stocks and microcaps. SmallCapReview has built a loyal opt-in following for their investor products by providing a newsletter at no cost, sent to subscribers, highlighting select stocks in play, to register visit www.SmallCapReview.com.
